"The drugmaker then said that its investigational compound olaparib would not progress into Phase III development for the maintenance treatment of serous ovarian cancer. Additionally, attempts to identify a suitable tablet dose for use in Phase III studies were not successful."
Saturday, January 28, 2012
financial news: AstraZeneca cancels Olaparib trial
"The drugmaker then said that its investigational compound olaparib would not progress into Phase III development for the maintenance treatment of serous ovarian cancer. Additionally, attempts to identify a suitable tablet dose for use in Phase III studies were not successful."
Subscribe to:
Post Comments (Atom)
Posts
0 comments:
Post a Comment